Gain Therapeutics Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
28 Mar 24 | BuyUS$115,770 | Jeffrey Riley | Individual | 30,000 | US$3.86 | |
07 Dec 23 | SellUS$4,550 | Matthias Alder | Individual | 1,820 | US$2.50 |
Insider Trading Volume
Insider Buying: GANX insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Private Companies | 4,892 | 0.0271% |
Individual Insiders | 1,952,119 | 10.8% |
Institutions | 2,488,699 | 13.8% |
General Public | 13,606,269 | 75.4% |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.5%.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
880,784 | US$2.6m | 0% | no data | |||
729,737 | US$2.1m | 0% | no data | |||
685,072 | US$2.0m | 0% | no data | |||
588,410 | US$1.7m | 0% | 0.09% | |||
287,458 | US$842.3k | 0% | no data | |||
260,019 | US$761.9k | 993% | no data | |||
200,248 | US$586.7k | -4.64% | no data | |||
151,476 | US$443.8k | 0% | no data | |||
90,000 | US$263.7k | 0% | 0.26% | |||
88,385 | US$259.0k | 25.8% | no data | |||
65,394 | US$191.6k | 42.6% | no data | |||
58,100 | US$170.2k | 0% | 0.02% | |||
46,100 | US$135.1k | 0% | no data | |||
43,513 | US$127.5k | 228% | no data | |||
42,800 | US$125.4k | -8.74% | no data | |||
34,500 | US$101.1k | -47.1% | no data | |||
30,000 | US$87.9k | 0% | no data | |||
27,611 | US$80.9k | -1.12% | no data | |||
21,140 | US$61.9k | 300% | no data | |||
17,983 | US$52.7k | 0% | no data | |||
15,886 | US$46.5k | -5.55% | no data | |||
14,023 | US$41.1k | 68.9% | no data | |||
12,764 | US$37.4k | 0% | no data | |||
11,453 | US$33.6k | 0% | 0.01% | |||
10,000 | US$29.3k | 0% | no data |